Business Context and Reporting Period
This Form 8-K Current Report, dated August 1, 2025, pertains to Geron Corporation (GERN), a biotechnology company incorporated in Delaware. The filing reports on corporate governance changes and executive compensation arrangements effective August 1, 2025, and August 7, 2025.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and equity plan amendments.
- CEO Base Salary: $800,000 annually.
- CEO Target Bonus: 70% of base salary ($560,000), prorated for 2025.
- CEO Equity Grant: Stock options to purchase 11,000,000 shares of common stock.
- Equity Plan Amendment: Increase of 11,000,000 shares authorized under the 2018 Inducement Award Plan.
Material Changes
The primary material change is the appointment of Harout Semerjian as President, Chief Executive Officer, and a Class I Director, effective August 7, 2025. He replaces Dawn C. Bir, who served as Interim President and CEO. Ms. Bir will remain on the Board of Directors.
Additionally, the Compensation Committee approved an amendment to the Company's Severance Plan to include a specific provision for the CEO: upon a Change of Control triggering a Separation of Service, the CEO is entitled to an additional payment equal to 150% of their annual target bonus, in addition to standard severance benefits.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of market risks. Management commentary is limited to the Board's rationale for appointing Mr. Semerjian, citing his deep commercial and hematology expertise and global leadership experience.
Compensation Contingencies:
- Severance: In the event of a Covered Termination, Mr. Semerjian is eligible for 18 months of base salary, a prorated target bonus, and 18 months of COBRA coverage.
- Change in Control: Stock options fully vest upon a Change in Control. Under the amended Severance Plan, a Change of Control triggering event entitles the CEO to 18 months of base salary, the prorated target bonus, plus 150% of the target bonus, and 18 months of COBRA.
- Equity Vesting: The 11,000,000 stock options vest over 48 months (12.5% at 6 months, then monthly) and 48 months (25% at 1 year, then monthly), subject to continued service.
Investor Verification Checklist
- Verify the exact grant date and exercise price of the 11,000,000 stock options, which are tied to the closing price on the start date (August 7, 2025).
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Covered Termination" and "Change in Control."
- Confirm the impact of the 11,000,000 share increase on the 2018 Inducement Award Plan on existing shareholder dilution.
- Assess the financial impact of the new CEO compensation package relative to the company's current cash position and burn rate (data not provided in this filing).